ORUVAIL Trademark

Trademark Overview

On Tuesday, April 5, 2022, a trademark application was filed for ORUVAIL with the United States Patent and Trademark Office. The USPTO has given the ORUVAIL trademark a serial number of 97347424. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 30, 2024. This trademark is owned by Pharma Trademarks Inc.. The ORUVAIL trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical products, namely, a sustained release ketoprofen used to prevent inflammation and used as an analgesic
oruvail

General Information

Serial Number97347424
Word MarkORUVAIL
Filing DateTuesday, April 5, 2022
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 30, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 4, 2023

Trademark Statements

Goods and Servicespharmaceutical products, namely, a sustained release ketoprofen used to prevent inflammation and used as an analgesic

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 11, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePharma Trademarks Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCheyenne, WY 82001
Party NamePharma Trademarks Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCheyenne, WY 82001

Trademark Events

Event DateEvent Description
Friday, April 8, 2022NEW APPLICATION ENTERED
Monday, April 11, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, August 11, 2022ASSIGNED TO EXAMINER
Thursday, August 11, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, August 11, 2022PREVIOUS ALLOWANCE COUNT WITHDRAWN
Thursday, August 18, 2022NON-FINAL ACTION WRITTEN
Thursday, August 18, 2022NON-FINAL ACTION E-MAILED
Thursday, August 18, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, May 19, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 10, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, May 19, 2023ASSIGNED TO LIE
Friday, May 19, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, May 22, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 30, 2023LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, July 4, 2023PUBLISHED FOR OPPOSITION
Wednesday, June 14, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 29, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 4, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, February 26, 2024SOU TEAS EXTENSION RECEIVED
Monday, February 26, 2024SOU EXTENSION 1 GRANTED
Monday, February 26, 2024SOU EXTENSION 1 FILED
Monday, September 30, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, September 30, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Tuesday, February 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

oruvail used prevent inflammation analgesic ketoprofen release products namely sustained pharmaceutical